Sell-Side M&A Advisory for Pharma and Life Sciences

Owners divest GMP manufacturing facilities for many reasons: portfolio realignment, network consolidation, shifting modality mix, or post-merger consolidation. We’ve represented sellers across small-molecule, biologic, cell and gene therapy, and ATMP facilities. Buyers include strategic acquirers, regional CDMOs, financial sponsors, and operating partners building new platforms.

Facilities rarely transact based on square footage alone. A successful pharmaceutical facility divestiture depends on positioning the facility around what a buyer actually values, including the validated capacity, regulatory track record, proximity to talent, and the cost to bring the asset to operational standard. We present the operational reality, not just the square footage, and we manage buyer access carefully to protect facility staff and ongoing operations.

Therapeutic asset sales cover the divestiture of approved products, late-stage clinical assets, and platform technologies, often when the original developer has shifted strategic focus. Each transaction requires a buyer who can take the asset forward commercially, technically, and regulatorily, which sharply narrows the realistic buyer pool.

We position therapeutic assets around the reasons a buyer will transact: a differentiated mechanism, durable IP, proven manufacturability, near-term revenue, or strategic fit with an existing pipeline. Pharmaceutical mergers and acquisitions in this category often involve milestone-based structures and royalty tails, which we model and negotiate alongside the headline deal value.

Network consolidations are multi-facility divestitures driven by overcapacity, post-merger optimization, or modality migration. Selling several facilities over a 12- to 24-month window requires sequencing, separate buyer pools for each asset, and careful coordination to ensure that each transaction doesn’t weaken the next transaction’s valuation.

We’ve run network consolidations for top-20 pharma companies and mid-cap specialty firms. The work covers facility-by-facility positioning, buyer outreach across the global pool, transaction sequencing, and the operational handover work that keeps each site running through closing. GMP facility sale valuations in network deals depend heavily on this sequencing.

Not every asset in a pharma portfolio belongs in the long-term plan. We work with senior leadership to assess which products, brands, or pipeline assets are candidates for divestiture, retention, or partnering, based on clinical fit, manufacturing economics, and buyer demand patterns.

The output is a defensible portfolio strategy and a prioritized divestiture sequence, not a one-time list. We then execute the resulting pharma sell-side advisory mandates as integrated transactions, keeping portfolio analysis and deal execution connected rather than handing them off between separate consulting and banking teams.

Every sell-side asset has a defensible value proposition, but it doesn’t always align with what the seller has been communicating internally. Buyers pay for what they can do with the asset, not for what it meant to the previous owner.

A well-done value proposition shapes everything downstream, including the buyer shortlist, the CIM, the management presentation, the negotiation positions, and the eventual sale price.